GSK plc (LON:GSK) Receives GBX 2,034.29 Average Target Price from Brokerages

Shares of GSK plc (LON:GSK) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is GBX 2,034.29.

Several analysts have recently issued reports on the stock. Berenberg Bank reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Citigroup cut their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 target price on shares of GSK in a research report on Monday, June 8th.

Insider Buying and Selling

In other news, insider Wendy Becker purchased 4,000 shares of the stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of GBX 1,963 per share, with a total value of £78,520. Also, insider Jonathan Symonds acquired 1,550 shares of GSK stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average cost of GBX 1,935 per share, with a total value of £29,992.50. Insiders acquired 7,625 shares of company stock worth $21,347,004 over the last quarter. 0.20% of the stock is owned by corporate insiders.

GSK Price Performance

GSK stock opened at GBX 1,910.39 on Friday. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The business’s 50 day simple moving average is GBX 1,928.33 and its 200 day simple moving average is GBX 1,986.18. The company has a market cap of £76.52 billion, a price-to-earnings ratio of 13.44, a PEG ratio of 1.24 and a beta of 0.30.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Sell-side analysts forecast that GSK will post 175.980975 EPS for the current year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.